Association of Aqueous Humor Cytokines With the Development of Retinal Ischemia and Recurrent Macular Edema in Retinal Vein Occlusion

2014 ◽  
Vol 55 (4) ◽  
pp. 2290 ◽  
Author(s):  
Sang Hoon Jung ◽  
Kyung-A. Kim ◽  
Sea Woon Sohn ◽  
Sung Jae Yang
Author(s):  
Xiaojing Xiong ◽  
Xu Chen ◽  
Huafeng Ma ◽  
Zheng Zheng ◽  
Yazhu Yang ◽  
...  

Macular edema (ME) is the main cause of visual impairment in patients with retinal vein occlusion (RVO). The degree of ME affects the prognosis of RVO patients, while it lacks objective laboratory biomarkers. We aimed to compare aqueous humor samples from 28 patients with retinal vein occlusion macular edema (RVO-ME) to 27 age- and sex-matched controls by ultra-high-performance liquid chromatography equipped with quadrupole time-of-flight mass spectrometry, so as to identify the key biomarkers and to increase the understanding of the mechanism of RVO-ME at the molecular level. Through univariate and multivariate statistical analyses, we identified 60 metabolites between RVO-ME patients and controls and 40 differential metabolites in mild RVO-ME [300 μm ≤ central retinal thickness (CRT) < 400 μm] patients compared with severe RVO-ME (CRT ≥ 400 μm). Pathway enrichment analysis showed that valine, leucine, and isoleucine biosynthesis; ascorbate and aldarate metabolism; and pantothenate and coenzyme A biosynthesis were significantly altered in RVO-ME in comparison with controls. Compared with mild RVO-ME, degradation and biosynthesis of valine, leucine, and isoleucine; histidine metabolism; beta-alanine metabolism; and pantothenate and coenzyme A biosynthesis were significantly changed in severe RVO-ME. Furthermore, the receiver operating characteristic (ROC) curve analysis revealed that adenosine, threonic acid, pyruvic acid, and pyro-L-glutaminyl-l-glutamine could differentiate RVO-ME from controls with an area under the curve (AUC) of >0.813. Urocanic acid, diethanolamine, 8-butanoylneosolaniol, niacinamide, paraldehyde, phytosphingosine, 4-aminobutyraldehyde, dihydrolipoate, and 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide had an AUC of >0.848 for distinguishing mild RVO-ME from severe RVO-ME. Our study expanded the understanding of metabolomic changes in RVO-ME, which could help us to have a good understanding of the pathogenesis of RVO-ME.


Retinal vein occlusion (RVO) is the second most common retinal vascular disease after diabetic retinopathy. RVO exists in two subtypes: CRVO (central retinal vein occlusion), which is less common and represents occlusion of the central retinal vein, and BRVO (branch retinal vein occlusion), which is 4-6 times more common and represents occlusion of some branches of central retinal vein. RVO is a relatively common and frequently devastating cause of visual loss mainly in older patients. Its prevalence varies according to studies in overall populations from 5.2 to 16 per 1000. Visual acuity is primarily decreased due to macular edema and retinal ischemia.


2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Aditya Modi ◽  
Karen Sharma ◽  
Neha Peraka Sudhakar ◽  
Naresh Kumar Yadav

Retinal vein occlusion (RVO) is one of the most common causes of acquired retinal vascular anomalies in adults and is a common cause of visual loss. There is little data on the prevalence of RVO in the general population, although it is at least as early as 1855 and there are more than 3000 publications. The number of studies on the incidence of RVO is relatively small. Reduced vision in patients affected by RVO can result from retinal ischemia and/or accumulation of fluid in the center of the retina (macular edema). In this review, studies on epidemiology, prevalence, and incidence in central retinal vein occlusion and macular edema were summarized and evaluated.


2018 ◽  
Vol 61 (4) ◽  
pp. 218-225 ◽  
Author(s):  
Taneto Tomiyasu ◽  
Yoshio Hirano ◽  
Norihiro Suzuki ◽  
Yuya Esaki ◽  
Yusuke Yasuda ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document